This issue of the BELLE Newsletter is devoted to an assessment of epigenetic carcinogens and the shape of the dose-response curve, especially at low doses. As has been typical of past BELLE Newsletters, the intent is to provide a forum to discuss and debate cutting edge issues by scientific leaders on the topic at hand. The format followed involved the presentation of a "white paper" on the topic by Professor James E. Klaunig and his colleagues at Indiana University in Indianapolis. This is followed by commentaries by highly experienced researchers in this field. Finally, Dr. Klaunig is given the opportunity to comment on and/or rebut the commentaries of the invited expert commentators.